Medical devices, healthcare technology and the business of care
510(k) clearance · K253490

Glucose HK Gen.3; ONLINE DAT Methadone II; cobas pro integrated solutions

Roche Diagnostics · Decision date Feb 12, 2026

FDA DECISIONK253490

What did the FDA decide?

FDA records K253490 as a 510(k) premarket notification, with a decision dated Feb 12, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Clinical Chemistry
Decision date
Feb 12, 2026

FDA source record

Regulatory record facts

Identifier
K253490
Regulatory pathway
510(k) premarket notification
Product code
CFR
Decision code
SESE
Decision date
Feb 12, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Hexokinase, Glucose.

Product code
CFR
FDA device class
2

FDA decision timeline

  1. K253490 received

    Application receipt date recorded by FDA.

  2. K253490 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Diagnostics

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Indianapolis, IN

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records